Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.
Over the decades, the American Society of Health-System Pharmacists (ASHP) has been there during the career of Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST.
At this year’s ASHP Midyear Clinical Meeting & Exposition, Chisholm-Burns, executive vice president and provost at Oregon Health and Science University, will be receiving the ASHP Board of Directors’ Distinguished Leadership Award for her work in pharmacy practice leadership and academic pharmacy.
Transcript
What is the ASHP Board of Directors’ Distinguished Leadership Award, and what work have you done leading to you receiving this award at the 2023 ASHP Midyear Clinical Meeting & Exposition?
First, I want to thank ASHP Board of Directors for selecting me for the Distinguished Leadership Award. The award, to my understanding, is for individuals who have excellence in pharmacy practice leadership. I've done several things not only in pharmacy practice, but also in pharmacy practice leadership, including academic pharmacy, so I'm just honored.
ASHP is an organization that really means a lot to me. It's probably been there since the beginning with [my] residency training. I don't want to age myself here, but it's been decades that we have been friends and on this journey together. I also had the honor of being the founding chair, and now the past chair of the ASHP's new Section of Pharmacy Educators. And so that means a lot to me. It means a lot that ASHP has asked me to be involved in several things over the years.
So, that's a little bit about the award. I'm looking forward to receiving the award. My husband, John, is going to be there. And I'm just looking forward to seeing people again. I’m very excited about many things. Life is good.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More